Abstract
In this paper we describe the optimisation of a phenotypic hit against Plasmodium falciparum, based on a tri-substituted pyrimidine scaffold. This led to compounds with good pharmacokinetics and oral activity in a P. berghei mouse model of malaria. The most promising compound (13) showed a reduction in parasitaemia of 96% when dosed at 30 mg/kg orally, once a day for 4 days in the P. berghei mouse model of malaria. It also demonstrated a rapid rate of clearance of the erythrocytic stage of P. falciparum in the SCID mouse model with an ED90 11.7 mg/kg when dosed orally. Unfortunately, the compound is a potent inhibitor of cytochrome P450 enzymes, probably due to a 4-pyridyl substituent. Nevertheless, this is a lead molecule with a potentially useful antimalarial profile, which could either be further optimised or used for target hunting.
| Original language | English |
|---|---|
| Pages (from-to) | 6101-6120 |
| Number of pages | 20 |
| Journal | Journal of Medicinal Chemistry |
| Volume | 59 |
| Issue number | 13 |
| Early online date | 17 Jun 2016 |
| DOIs | |
| Publication status | Published - 14 Jul 2016 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Trisubstituted Pyrimidines as Efficacious and Fast-acting Antimalarials'. Together they form a unique fingerprint.Projects
- 1 Finished
-
A Translational Engine for Biomedical Discoveries (Strategic Grant)
Fairlamb, A. (Investigator) & Gilbert, I. (Investigator)
1/01/13 → 30/09/15
Project: Research
Profiles
-
Gilbert, Ian
- Drug Discovery Unit - Professor/Head of the Drug Discovery Unit & Roscoe Chair in Drug Discovery
Person: Academic
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver